Deep Learning-Enhanced Paper-Based Vertical Flow Assay for High-Sensitivity Troponin Detection Using Nanoparticle Amplification

• Published in: ACS nano Vol. 18; no. 41; pp. 27933 - 27948
• Main Authors: Han, Gyeo-Re, Goncharov, Artem, Eryilmaz, Merve, Joung, Hyou-Arm, Ghosh, Rajesh, Yim, Geon, Chang, Nicole, Kim, Minsoo, Ngo, Kevin, Veszpremi, Marcell, Liao, Kun, Garner, Omai B., Di Carlo, Dino, Ozcan, Aydogan
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 15.10.2024
• Subjects: Biomarkers - blood; Biosensing Techniques - instrumentation; Colorimetry - instrumentation; Colorimetry - methods; Deep Learning; Gold - chemistry; Humans; Limit of Detection; Nanoparticles - chemistry; Point-of-Care Testing; Troponin I - analysis; Troponin I - blood; cardiovascular disease; high sensitivity; deep learning; troponin; vertical flow assay; nanoparticle amplification; point-of-care
• ISSN: 1936-0851; 1936-086X; 1936-086X
• DOI: 10.1021/acsnano.4c05153

Successful integration of point-of-care testing (POCT) into clinical settings requires improved assay sensitivity and precision to match laboratory standards. Here, we show how innovations in amplified biosensing, imaging, and data processing, coupled with deep learning, can help improve POCT. To demonstrate the performance of our approach, we present a rapid and cost-effective paper-based high-sensitivity vertical flow assay (hs-VFA) for quantitative measurement of cardiac troponin I (cTnI), a biomarker widely used for measuring acute cardiac damage and assessing cardiovascular risk. The hs-VFA includes a colorimetric paper-based sensor, a portable reader with time-lapse imaging, and computational algorithms for digital assay validation and outlier detection. Operating at the level of a rapid at-home test, the hs-VFA enabled the accurate quantification of cTnI using 50 μL of serum within 15 min per test and achieved a detection limit of 0.2 pg/mL, enabled by gold ion amplification chemistry and time-lapse imaging. It also achieved high precision with a coefficient of variation of <7% and a very large dynamic range, covering cTnI concentrations over 6 orders of magnitude, up to 100 ng/mL, satisfying clinical requirements. In blinded testing, this computational hs-VFA platform accurately quantified cTnI levels in patient samples and showed a strong correlation with the ground truth values obtained by a benchtop clinical analyzer. This nanoparticle amplification-based computational hs-VFA platform can democratize access to high-sensitivity point-of-care diagnostics and provide a cost-effective alternative to laboratory-based biomarker testing.